SynthesisFrontiers in pharmacology2023
Effect of potassium-competitive acid blockers on human gut microbiota: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Beyond gastric acid: pharmacologic modulation of the tumor microenvironment by vonoprazan and its drug-interaction implications for chemotherapy and immunotherapy.Cancer chemotherapy and pharmacology · 2026Review
- Association of probiotic use with nivolumab efficacy in gastric cancer patients on gastric acid suppressants.iScience · 2026Article
- Article
- A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.Microorganisms · 2026Article
- Gatherings in Esophagology: Innovations and Future Directions in the Diagnosis and Management of Reflux Disease.Annals of the New York Academy of Sciences · 2026Article
- Association of Proton Pump Inhibitor and Potassium-Competitive Acid Blocker Use With Discontinuation and Intolerance of Oral 5-Aminosalicylic Acid in Patients With Ulcerative Colitis.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer.Immunotherapy · 2025Article
- Effect of tegoprazan, a novel potassium-competitive acid blocker, on non-steroidal anti-inflammatory drug (NSAID)-induced enteropathy.Scientific reports · 2024Article
- Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers vs. Proton Pump Inhibitors for Peptic Ulcer with or withoutPharmaceuticals (Basel, Switzerland) · 2024Review
- Vonoprazan-associatedTherapeutic advances in drug safety · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.